ESC: Cyclosporine Fails to Prevent Reperfusion Injury
(MedPage Today) -- No reduction in left ventricular remodeling, according to CIRCUS study results (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - August 30, 2015 Category: Journals (General) Source Type: news
Cyclosporine does not improve outcomes after PCI
(European Society of Cardiology) The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention for the more severe form of heart attack known as ST-segment elevation myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2015 Category: Global & Universal Source Type: news
Pharmaceutics and Drug Delivery - 2002
Guest Editor(s) Bruce Aungst Introduction Pharmaceutics and drug delivery Author(s) Bruce Aungst Role of plasma lipoproteins in modifying the toxic effects of water insoluble drugs Studies with cyclosporine A Author(s) Kishor M. Wasan Manisha Ramaswamy Mona Kwong Kathy D. (Source: AAPS Publications)
Source: AAPS Publications - August 19, 2015 Category: Drugs & Pharmacology Source Type: news
Allergan closes $125m Oculeve buy
Allergan said yesterday it closed its purchase of dry eye disease device developer Oculeve for $125 million in up-front payments in addition to unspecified commercialization milestones.
South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. Oculeve has completed 4 clinical trials of OD-01 to date.
“The acquisition of Oculeve further enhances Allergan’s world-class position in eye care and underscores our commitment to continuing to develop a broad range of treatme...
Source: Mass Device - August 11, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Optical/Ophthalmic Allergan Inc. Oculeve Source Type: news
WCD: Methotrexate found safer but less effective than cyclosporine in atopic dermatitis
VANCOUVER, B.C. – In the first head-to-head trial in atopic dermatitis, cyclosporine was about five times more effective in terms of SCORAD 50 but was associated with more adverse events, Dr. Catherine Goujon-Henry reported at the World Congress of Dermatology.
Based on the findings,...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 27, 2015 Category: Dermatology Tags: SAN Conference News IMN Conferences SAN Atopic Dermatitis SAN Clinical News SAN News IMN News IMN Dermatology Source Type: news
Topical Cyclosporine Better for Ocular RosaceaTopical Cyclosporine Better for Ocular Rosacea
A new comparative study has found that topical cyclosporine is more effective than oral doxycycline at relieving symptoms and treating eyelid and dry eye signs in patients with ocular rosacea. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 27, 2015 Category: Dermatology Tags: Ophthalmology News Source Type: news
There's Relief In Sight For People With Perpetually Dry Eyes
By Janice Neumann (Reuters Health) - Tiny plugs inserted into the tear duct may safely curb the annoying and damaging effects of dry eyes, according to a new analysis of previous research. "Plugs are generally well tolerated," said Dr. Marcus Marcet, an ophthalmologist at the University of Hong Kong and the study's first author. "Overall the extent of relief depends on both the type of dry eye and the type of plug." Patients with dry eyes who might benefit from plugs are those who have already tried eye drops and gels but still have itchy, red, painful eyes, blurred vision and the sensation of a foreign body in the eye, ...
Source: Science - The Huffington Post - June 23, 2015 Category: Science Source Type: news
Consider combining therapies for atopic dermatitis
Cyclosporine and oral antihistamine therapy showed inconsistent effects on clinical and laboratory markers of atopic dermatitis in older children and adults, based on data from a study of 48 patients.
A total of 25 patients aged 16-42 years received oral cyclosporine and 23 patients aged 15-32...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 9, 2015 Category: Dermatology Tags: IMN News IMN Dermatology FPN News FPN Dermatology SAN Clinical News SAN News SAN Atopic Dermatitis Source Type: news
3-D printed, mechanically robust carrier used to deliver immunosuppressive drug, and cells
(Cell Transplantation Center of Excellence for Aging and Brain Repair) After a 3-D printer was used to create a micro but mechanically robust drug and cell carrier for local and sustained delivery of the immunosuppressive drug cyclosporine, researchers demonstrated in tests with animal models that the carrier, a combination of microspheres and hydrogel, maintained robust shape and integrity and delivered a local, sustained release of CsA in an amount that prevented acceleration of cytokines and overcame the need for additional drugs to treat immune rejection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2015 Category: Global & Universal Source Type: news
The Hearts Of Mary Shelley
"Perhaps a corpse would be reanimated... perhaps the components parts of a creature might be manufactured, brought together and endued with vital warmth."
-Mary Shelley
On Valentine's Day, we consider the heart. The heart is biological; it is the organ on which our life most depends. The heart is emotional, full of love and sorrow. The heart is wandering. No one knew our central muscle's multiple meanings better than Mary Shelley.
Mary Shelley was a writer's writer, depressive, miserable, and brilliant. So too the friends she gathered with, at the age of 18, in the spring of 1816 at two adjacent houses on Lake Geneva...
Source: Science - The Huffington Post - February 11, 2015 Category: Science Source Type: news
Celgene’s Otezla® (apremilast) receives European marketing authorisation
Celgene UK announced that the European Commission has licenced Otezla®, the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (2)
For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Alone or in combination with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis in adult patients who have had an inadequate r...
Source: Pharmacy Europe - January 16, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Dermatology Rheumatology Patient care chronic plaque psoriasis DMARD Latest News PDE4 inhibitor psoriatic arthritis PUVA Source Type: news
Dollars for Dudes: Almost no women among medical industry's top-paid speakers, consultants
The causes are not clear, but men account for more than 90 percent of the 300 doctors who received the most money from drug and medical device companies, according to new federal data.
Alison Tendler, an ophthalmologist who works in Sioux Falls, S.D., is among the few women on a list of the doctors paid the most money by drug companies last year. That's primarily because she serves as the TV advertising spokeswoman for the eye drug Restasis.
Centers for Medicare and Medicaid Services (CMS), ProPublicaNews Well, Medicareread more (Source: Mass Device)
Source: Mass Device - October 8, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news
How Does Pediatric Psoriasis Present?
Discussion
Psoriasis is an inflammatory skin disease that is chronic and relapsing with periods of remission. It occurs in genetically susceptible persons and is felt to be triggered by environmental factors including infection (especially Group A, β-hemolytic streptococcus), emotional and physical stress, and skin irritation including friction, rubbing, pressure and scratching. It is common in patients with certain HLA types including HLA-Cw*0602, HLA-Cw6, IL-15 plus others.
It occurs in about 1% of the general population with two age-onset peaks: 16-22 years and ~60 years, but can occur at any age. Some studies show...
Source: PediatricEducation.org - April 14, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2013 Category: Pharmaceuticals Source Type: news
Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Media News)
Source: Roche Media News - July 19, 2013 Category: Pharmaceuticals Source Type: news
